Elizabeth Nielson
Chief Executive Officer & Co-Founder of Fluence; psychologist and psychedelic therapist
Data updated
Research Footprint
Elizabeth Nielson appears in 8 tracked papers (2018–2024), most studied alongside Psilocybin and MDMA, across Substance Use Disorders (SUD), Equity and Ethics and Depressive Disorders.
Most-cited paper: Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression (1057 citations).
Frequent co-authors: Ekaterina Malievskaia, Michael Bogenschutz and Michael Mithoefer.
Background & Research
Elizabeth M. Nielson is a psychologist and therapist whose work focuses on psychedelic-assisted psychotherapy, therapist training, and harm reduction/integration practices. She has been affiliated with New York State Psychiatric Institute/Columbia University and has contributed to studies on psilocybin therapy, psychedelic therapists’ experiences, and ethical/policy frameworks for psychedelic clinical care. She is also a co-founder and leader at Fluence, where she develops clinician education programs in psychedelic therapy.
Key Impact
She is a prominent clinician-researcher and trainer in psychedelic-assisted therapy, known for work on therapist training, harm reduction, and integration in psychedelic clinical care.
Collaboration Network
43 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Elizabeth Nielson is associated with.
Fluence
Specialized psychedelic clinical trial services provider focused on therapist and facilitator training, protocol/manual support, adherence frameworks, and sponsor-facing trial preparation.
View stakeholder →MAPS
nonprofitMAPS, the Multidisciplinary Association for Psychedelic Studies, is a U.S.-based 501(c)(3) nonprofit research and educational organization founded in 1986. It works nationally and with a broader global audience to develop medical, legal, and cultural contexts for the careful use of psychedelics and marijuana. Its core activities include research, education, advocacy, and convening the field through large public events. In psychedelic medicine and policy, MAPS positions itself as an advocate for legal access, drug policy reform, harm reduction, and health equity. Its Policy & Advocacy work includes legislative advocacy, community organizing, and impact litigation, and it has also launched work on access for system-impacted people and broader health equity in the legal psychedelic ecosystem. Current documented initiatives include the Psychedelic Science conference series, the Health Equity Program, The Zendo Project, and Ask MAPS, which handles public inquiries about therapy, research, and policy reform.
View stakeholder →Psychedelic Medicine Association
nonprofitThe Psychedelic Medicine Association (PMA) is a professional association that educates and connects healthcare practitioners about the therapeutic use of psychedelic medicines. It also develops clinical practice guidelines, training accreditation, and related infrastructure to support safe integration of psychedelic therapies into mainstream healthcare.
View stakeholder →COMPASS Pathways
Public BiotechCOMPASS Pathways is a UK-listed biopharmaceutical company developing COMP360 synthetic psilocybin therapy for treatment-resistant depression, with two successful Phase 3 trials making it the leading candidate for the first regulatory approval of a classic psychedelic medicine.
View stakeholder →New York University
academicThe Center for Psychedelic Medicine at NYU Langone Health is directed by Dr. Michael Bogenschutz and performs health-focused research across the translational spectrum, from basic science to large-phase clinical trials. The center has three transdisciplinary areas of focus: psychiatry, medicine, and preclinical research. Currently, the team is actively investigating clinical applications for various psychedelic compounds, leading robust studies on psilocybin-assisted therapy for alcohol use disorder, major depression, and advanced cancer-related psychiatric distress.
View stakeholder →